1
Nandini Katre, Robert F Halenbeck, Robert J Goodson, Peter C McCabe, Michael J Knauf: Interleukin-2 muteins and polymer conjugation thereof. Cetus Oncology Corporation, Philip L McGarrigle, Janet E Hasak, April 27, 1993: US05206344 (228 worldwide citation)

Muteins of IL-2 in which one of the amino acids of the mature native sequence of IL-2 is replaced by a cysteine residue are prepared and conjugated through the replaced cysteine residue to a polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols, wherein said homopolymers ...


2
Danute E Nitecki: Preparation of an activated polymer ester for protein conjugation. Cetus Oncology Corporation, Grant D Green, Kenneth M Goldman, Philip L McGarrigle Jr, January 25, 1994: US05281698 (226 worldwide citation)

The present invention is a process for preparing an activated ester of polyethylene glycol or a polyoxyethylated polyol. After the activated ester is prepared, it can be reacted with a protein to form a polymer/protein conjugate. Conjugation with a polymer can reduce the protein's immunogenicity, in ...


3
Arthur E Frankel, David B Ring, Walter Laird: Cetus Oncology Corporation, Gregory J Giotta, Scott R Bortner, Philip L McGarrigle, December 8, 1992: US05169774 (67 worldwide citation)

Murine monoclonal antibodies, or fragments thereof, that bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitorin ...


4
Michael V Doyle, Arthur D Newell, Jack H Nunberg, Thomas J White: Human IL-2 as a vaccine adjuvant. Cetus Oncology Corporation, Barbara G McClung, Thomas C Meyers, Robert P Blackburn, April 2, 1996: US05503841 (35 worldwide citation)

Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine e ...


5
David B Ring, Arthur E Frankel, Michael J Bjorn: Cetus Oncology Corporation, Paul B Savereide, Grant D Green, Robert P Blackburn, May 13, 1997: US05629197 (34 worldwide citation)

Murine monoclonal antibodies are prepared and characterized which bind selectively to high molecular weight mucins by immunoprecipitation test and are IgGs or IgMs. Immunotoxins comprising the monoclonal antibody and cytotoxic moiety were produced.


6
Mark De Boer, Leah B Conroy: Method for generation of antibodies to cell surface molecules. Cetus Oncology Corporation, Thomas C Meyers, Paul B Savereide, Robert P Blackburn, March 14, 1995: US05397703 (27 worldwide citation)

The present invention relates to a method of generating antibodies directed against cell surface antigens. The method uses as immunogen recombinant insect cells into which have been transfected coding regions for a molecule containing a cell surface antigen. Host animals are immunized with these tra ...


7
Michael Kriegler, Carl Perez: Human Y-interferon signal peptide-tumor necrosis factor(TNF) gene fusions. Cetus Oncology Corporation, Lewis S Gruber, Kenneth M Goldman, Robert P Blackburn, June 28, 1994: US05324655 (22 worldwide citation)

A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes ...


8
Just P J Brakenhoff, Lucien A Aarden: Interleukin-6 receptor antagonists. Cetus Oncology Corporation, Li Hsien Rin Laures, Paul B Savereide, Robert P Blackburn, January 7, 1997: US05591827 (20 worldwide citation)

This invention provides a class of interleukin-6 (IL-6) muteins which act as IL-6 receptor antagonists, thereby inhibiting the normal function of naturally-occurring IL-6. These IL-6 receptor antagonists are preferably IL-6 molecules containing one or more mutations in the Site II region comprising ...


9
Frank P McCormick, Kirston E Koths, Robert F Halenbeck, Mary M Trahey: Compositions for detecting ras gene proteins and cancer therapeutics. Cetus Oncology Corporation, Lewis S Gruber, Gregory J Giotta, August 10, 1993: US05234839 (18 worldwide citation)

Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whe ...


10
Robert Zimmerman, Benedict J Marafino Jr: Method for treating biological damage using a free-radial scavenger and interleukin-2. Cetus Oncology Corporation, David A Gass, Paul B Savereide, Robert P Blackburn, April 16, 1996: US05508031 (17 worldwide citation)

Damage to cells, tissue and other body parts in a mammalian host may be treated by using a lymphokine or cytotoxin in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphox ...